Angle reports further delays on IVF product

Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure.

The embryo viability product is being developed by Novocellus, which is 82% owned by Angle.

The firm had already said the trial of EmbryoSure was delayed, but today added that the timeframe for completing the trials was "at present uncertain".

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Agnle would meet with Origio, the firm responisble for the trials, at the end of this month to review options for progressing the trials, it said.

"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible," said chief executive Andrew Newland.

Angle's share price fell 6% after the announcement.